2023
Basal Cell Skin Cancer, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
Schmults C, Blitzblau R, Aasi S, Alam M, Amini A, Bibee K, Bordeaux J, Chen P, Contreras C, DiMaio D, Donigan J, Farma J, Ghosh K, Harms K, Ho A, Lukens J, Mark L, Medina T, Nehal K, Nghiem P, Olino K, Park S, Patel T, Puzanov I, Rich J, Sekulic A, Shaha A, Srivastava D, Thomas V, Tomblinson C, Venkat P, Xu Y, Yu S, Yusuf M, McCullough B, Espinosa S. Basal Cell Skin Cancer, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2023, 21: 1181-1203. PMID: 37935106, DOI: 10.6004/jnccn.2023.0056.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsBasal cell carcinomaNCCN Clinical Practice GuidelinesClinical practice guidelinesSkin cancerTreatment optionsPractice guidelinesBasal cell skin cancerPrevalent treatment optionPrevious medical therapyLimitation of functionBCC occurrenceMedical therapyRisk stratificationBCC developmentCell carcinomaCancerCommon formOncologyAnnual rateEstimated ratesGuidelinesKey playersSurgeryCarcinomaHigh frequency
2021
Metabolism of Innate Immune Cells in Cancer
Talty R, Olino K. Metabolism of Innate Immune Cells in Cancer. Cancers 2021, 13: 904. PMID: 33670082, PMCID: PMC7927092, DOI: 10.3390/cancers13040904.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsInnate immune cellsImmune cellsAntitumor immune responseImmune checkpoint blockadeAdoptive cell transferOngoing clinical applicationsSpecific metabolic requirementsInnate immune systemCheckpoint blockadeTumor clearanceAntitumor responseImmune activationMetabolic requirementsT cellsImmune responseEffector functionsImmune systemCell transferTumor microenvironmentCancer cellsPrimary effectorClinical applicationCancerCellsMetabolism
2016
Palliative Care for Pancreatic and Periampullary Cancer
Perone JA, Riall TS, Olino K. Palliative Care for Pancreatic and Periampullary Cancer. Surgical Clinics Of North America 2016, 96: 1415-1430. PMID: 27865285, PMCID: PMC5119929, DOI: 10.1016/j.suc.2016.07.012.Peer-Reviewed Original ResearchConceptsMost patientsPalliative careGastric outlet obstructionRelief of painPancreatic cancer patientsAdvanced diseaseLocalized diseaseMultimodality therapyCeliac plexusOutlet obstructionPeriampullary cancerObstructive jaundiceCancer patientsPancreatic cancerPalliative techniquesPatientsCommon endpointCancerDiseaseReliefCareCare triangleFamily goalsJaundicePain
2014
A preclinical murine model of hepatic metastases.
Soares KC, Foley K, Olino K, Leubner A, Mayo SC, Jain A, Jaffee E, Schulick RD, Yoshimura K, Edil B, Zheng L. A preclinical murine model of hepatic metastases. Journal Of Visualized Experiments 2014, 51677. PMID: 25285458, PMCID: PMC4378377, DOI: 10.3791/51677.Peer-Reviewed Original ResearchConceptsHepatic metastasesMurine modelNumerous murine modelsPreclinical murine modelsTumor immunology researchPancreatic tumor modelPancreatic tumor cellsMurine pancreatic tumor modelMetastatic diseaseClinical conditionsMetastatic processTumor modelTherapy testingTumor cellsCancer treatmentMetastasisHuman cancersImmunology researchLiverModel mimicsPatientsCancerDiseaseMice
2012
Clinicopathological Characteristics and Molecular Analyses of Multifocal Intraductal Papillary Mucinous Neoplasms of the Pancreas
Matthaei H, Norris AL, Tsiatis AC, Olino K, Hong SM, dal Molin M, Goggins MG, Canto M, Horton KM, Jackson KD, Capelli P, Zamboni G, Bortesi L, Furukawa T, Egawa S, Ishida M, Ottomo S, Unno M, Motoi F, Wolfgang CL, Edil BH, Cameron JL, Eshleman JR, Schulick RD, Maitra A, Hruban RH. Clinicopathological Characteristics and Molecular Analyses of Multifocal Intraductal Papillary Mucinous Neoplasms of the Pancreas. Annals Of Surgery 2012, 255: 326-333. PMID: 22167000, PMCID: PMC3534752, DOI: 10.1097/sla.0b013e3182378a18.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinoma, MucinousAgedAged, 80 and overCarcinoma, Pancreatic DuctalCarcinoma, PapillaryClone CellsFemaleHumansLaser Capture MicrodissectionLoss of HeterozygosityMaleMiddle AgedMutationNeoplasms, Multiple PrimaryNeoplasms, Second PrimaryPancreatic NeoplasmsProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)Ras ProteinsRetrospective StudiesSequence Analysis, DNAConceptsMultifocal intraductal papillary mucinous neoplasmsIntraductal papillary mucinous neoplasmPapillary mucinous neoplasmMucinous neoplasmsClinicopathologic featuresPancreatic cancerClonal relationshipBranch duct lesionsCystic precursor lesionsFamilial pancreatic cancerKRAS gene mutationsIntermediate dysplasiaIndependent genetic alterationsDuct lesionsClinicopathological characteristicsInvasive cancerPrecursor lesionsPartial pancreatectomyPatientsNeoplasmsIntermediate gradeGene mutationsCancerGenetic alterationsMolecular analysis
2010
Immuno- and gene-therapeutic strategies targeted against cancer (mainly focusing on pancreatic cancer)
Yoshimura K, Olino K, Edil BH, Schulick RD, Oka M. Immuno- and gene-therapeutic strategies targeted against cancer (mainly focusing on pancreatic cancer). Surgery Today 2010, 40: 404-410. PMID: 20425541, DOI: 10.1007/s00595-009-4120-8.Peer-Reviewed Original ResearchConceptsCurrent treatment modalitiesNovel therapeutic approachesGene therapySurgical resectionTreatment arsenalTumor recurrenceCancer patientsTreatment modalitiesClinical trialsTherapeutic approachesGene therapeutic strategiesVivo modelCancerImmunotherapyTherapyFurther investigationPotential additionResectionChemotherapyPatientsRecurrenceMortalityTrialsCare
2009
Integrin α2 Mediates Selective Metastasis to the Liver
Yoshimura K, Meckel KF, Laird LS, Chia CY, Park JJ, Olino KL, Tsunedomi R, Harada T, Iizuka N, Hazama S, Kato Y, Keller JW, Thompson JM, Chang F, Romer LH, Jain A, Iacobuzio-Donahue C, Oka M, Pardoll DM, Schulick RD. Integrin α2 Mediates Selective Metastasis to the Liver. Cancer Research 2009, 69: 7320-7328. PMID: 19738067, PMCID: PMC4857201, DOI: 10.1158/0008-5472.can-09-0315.Peer-Reviewed Original ResearchConceptsHepatic metastasesColorectal cancerPrimary colorectal cancerHuman colorectal cancerIntegrin alpha2Organ-specific metastasisLiver metastasesLung metastasesAntibody blockadeIntegrin alpha2 expressionSelective metastasisIndividual patientsB16 melanomaCollagen type IVMetastasisAlpha2 expressionCell membrane moleculesMetastatic processB16-F0CancerType IVPossible targetsIntegrin α2LiverAlpha2The Current Management of Choledochal Cysts
Edil BH, Olino K, Cameron JL. The Current Management of Choledochal Cysts. Advances In Surgery 2009, 43: 221-232. PMID: 19845181, DOI: 10.1016/j.yasu.2009.02.007.ChaptersConceptsCholedochal cystCholedochal cyst diseaseLate complicationsCyst diseasePediatric populationSurgical excisionBiliary diseaseLiver fibrosisComplete excisionInterventional techniquesGeneral surgeonsAdult populationCurrent managementMalignant transformationCystsDiseaseType IVComplicationsExcisionDiagnosisPatientsFibrosisMRCPPopulationCancerSMAD4 Gene Mutations Are Associated with Poor Prognosis in Pancreatic Cancer
Blackford A, Serrano OK, Wolfgang CL, Parmigiani G, Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Eshleman JR, Goggins M, Jaffee EM, Iacobuzio-Donahue CA, Maitra A, Cameron JL, Olino K, Schulick R, Winter J, Herman JM, Laheru D, Klein AP, Vogelstein B, Kinzler KW, Velculescu VE, Hruban RH. SMAD4 Gene Mutations Are Associated with Poor Prognosis in Pancreatic Cancer. Clinical Cancer Research 2009, 15: 4674-4679. PMID: 19584151, PMCID: PMC2819274, DOI: 10.1158/1078-0432.ccr-09-0227.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overFemaleGene DeletionHumansKaplan-Meier EstimateMaleMiddle AgedMutationPancreatic NeoplasmsPrognosisProtein Serine-Threonine KinasesReceptor, Transforming Growth Factor-beta Type IIReceptors, Transforming Growth Factor betaSmad4 ProteinTumor Suppressor Protein p53ConceptsPoor prognosisPancreatic cancerLymph node statusShorter overall survivalSMAD4 gene mutationUnderwent pancreaticoduodenectomyOverall survivalMargin statusNode statusTumor sizePatient outcomesPatientsAdenocarcinomaPancreasCancerPrognosisGene mutationsSMAD4 inactivationGene inactivationSomatic mutationsHomozygous deletionMonthsSurvivalGenetic Mutations Associated with Cigarette Smoking in Pancreatic Cancer
Blackford A, Parmigiani G, Kensler TW, Wolfgang C, Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Eshleman JR, Goggins M, Jaffee EM, Iacobuzio-Donahue CA, Maitra A, Klein A, Cameron JL, Olino K, Schulick R, Winter J, Vogelstein B, Velculescu VE, Kinzler KW, Hruban RH. Genetic Mutations Associated with Cigarette Smoking in Pancreatic Cancer. Cancer Research 2009, 69: 3681-3688. PMID: 19351817, PMCID: PMC2669837, DOI: 10.1158/0008-5472.can-09-0015.Peer-Reviewed Original ResearchConceptsPancreatic cancerCigarette smokingGenetic Mutations AssociatedSomatic mutationsPancreatic cancer genomeCigarette smokersSmoking accountsPancreatic carcinomaDiscovery screenSmokersCarcinomaSmokingCancerMutations AssociatedMutational patternsAdenocarcinomaDriver genesPancreasCigarettesMore mutationsMutationsNonsynonymous mutationsNonsmokersPrevious studiesIndividuals